Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John J. Garber, M.D.

Co-Author

This page shows the publications co-authored by John Garber and Ashwin Ananthakrishnan.
Connection Strength

3.414
  1. Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study. Dig Dis Sci. 2020 12; 65(12):3672-3678.
    View in: PubMed
    Score: 0.227
  2. Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 03; 19(3):519-527.e5.
    View in: PubMed
    Score: 0.222
  3. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. J Crohns Colitis. 2020 Mar 13; 14(3):309-315.
    View in: PubMed
    Score: 0.222
  4. Second-Look Endoscopy in Hospitalized Severe Ulcerative Colitis: A Retrospective Cohort Study. Inflamm Bowel Dis. 2019 03 14; 25(4):750-755.
    View in: PubMed
    Score: 0.207
  5. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflamm Bowel Dis. 2018 07 12; 24(8):1840-1848.
    View in: PubMed
    Score: 0.198
  6. Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. Dig Dis Sci. 2018 10; 63(10):2740-2746.
    View in: PubMed
    Score: 0.197
  7. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clin Gastroenterol Hepatol. 2019 02; 17(3):502-509.e1.
    View in: PubMed
    Score: 0.197
  8. Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. J Crohns Colitis. 2018 Apr 27; 12(5):525-531.
    View in: PubMed
    Score: 0.195
  9. Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 07; 23(7):1234-1239.
    View in: PubMed
    Score: 0.184
  10. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. . 2017 May 10; 21(5):603-610.e3.
    View in: PubMed
    Score: 0.182
  11. Genetic risk factors for serious infections in inflammatory bowel diseases. Scand J Gastroenterol. 2017 May; 52(5):570-576.
    View in: PubMed
    Score: 0.179
  12. Erratum to: Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci. 2017 02; 62(2):552.
    View in: PubMed
    Score: 0.179
  13. Older Age- and Health-related Quality of Life in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2017 02; 23(2):283-288.
    View in: PubMed
    Score: 0.179
  14. The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 Mar; 45(6):814-823.
    View in: PubMed
    Score: 0.179
  15. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. Am J Gastroenterol. 2016 12; 111(12):1816-1822.
    View in: PubMed
    Score: 0.174
  16. Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study. Inflamm Bowel Dis. 2016 09; 22(9):2149-57.
    View in: PubMed
    Score: 0.174
  17. Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell. 2019 07 25; 178(3):714-730.e22.
    View in: PubMed
    Score: 0.053
  18. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 2017 Nov 28; 9(1):103.
    View in: PubMed
    Score: 0.047
  19. Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2017 07; 23(7):1088-1095.
    View in: PubMed
    Score: 0.046
  20. Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. Inflamm Bowel Dis. 2017 01; 23(1):82-88.
    View in: PubMed
    Score: 0.045
  21. Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis. Front Immunol. 2016; 7:554.
    View in: PubMed
    Score: 0.044
  22. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis. 2015 Dec; 21(12):2879-85.
    View in: PubMed
    Score: 0.041
  23. Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. Inflamm Bowel Dis. 2015 Oct; 21(10):2304-2310.
    View in: PubMed
    Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.